7506 Background: No standard of care exists for patients with advanced NSCLC and PS 2
and clinical practice ranges from supportive care to combination chemotherapy. Methods: In …

Purpose To compare single-agent pemetrexed (P) versus the combination of carboplatin
and pemetrexed (CP) in first-line therapy for patients with advanced non–small-cell lung …

Purpose To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in
pretreated patients with advanced non–small-cell lung cancer (NSCLC). Patients and …

8050 Background: The role of platinum compounds as part of second line therapies in
advanced NSCLC is ill defined. We performed a randomized phase II trial comparing P and …

Background Subgroup analyses of randomized studies have consistently shown that
pemetrexed is exclusively effective in non-small-cell lung cancer (NSCLC) other than …

7074 Background: P (Alimta), a multitargeted antifolate, inhibits thymidylate synthase,
dihydrofolate reductase and glycinamide ribonucleotide formyl transferase. P and cisplatin …

Background Pemetrexed plus cisplatin was approved for first-line treatment of non–small-
cell lung cancer (NSCLC) in patients with nonsquamous histology after initiation of this …

INTRODUCTION: The primary objectives of this study were to determine the recommended
dose of pemetrexed and carboplatin in patients with chemo-naive advanced non-small cell …

Over the past decade many large randomized trials have been conducted in patients with
locally advanced or metastatic non-small cell lung cancer (NSCLC); however, no single …

Purpose: To determine efficacy and toxicity of two pemetrexed-based regimens in
chemonaive patients with locally advanced or metastatic non–small cell lung cancer …